Table 1 Patient characteristics

From: Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome

(a)

Type of tumor

Normal adrenal glands

Aldosterone-producing adrenocortical adenoma

Cortisol-producing adrenocortical adenoma

Endocrine-inactive adrenocortical adenoma

N

5

12

10

9

Age

59 (44–83)

45 (31–69)

53 (35–73)

61 (43–76)

Sex (M/F)

1/4

6/6

1/9

3/6

Tumor size

—

2 (0.3–5)

3 (1.5–6)

4 (1–11)

(b) Adrenocortical carcinomas

ENSAT stage

I

II

III

IV

N

6

50

39

37

Age

63 (23–77)

46 (15–77)

53 (31–74)

48 (7–74)

Sex (M/F)

2/4

21/29

14/25

10/27

Tumor size

4.5 (3.0–5.0)

11 (6.0–28)

10 (5–20)

13 (6–25)

Functional status a

 Glucocorticoids±other steroids

3

17

11

18

 Mineralocorticoids only

0

3

2

1

 Sex hormones/precursors only

0

6

4

3

 Endocrine inactive

1

7

7

4

EGFR expression

 0

0

13

12

7

 1

1

9

8

6

 2

1

12

4

11

 3

4

16

15

13

  1. ENSAT, European Network for the Study of Adrenal Tumors staging system.47
  2. a In some patients no pre-surgical hormonal workup was performed.
  3. Data presented as median and range.
  4. Part (a) shows adrenocortical adenoma patients, and part (b) shows adrenocortical carcinoma patients in whom primary tumor was analyzed (in three patients, stage could not be determined).
Back to article page